Please Wait
Applying Filters...
menu
    • menu
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

    Stock Recap
    #PipelineProspector

    Menu

    Eribulin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,161,255Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    26/09/2024 BrightGene Bio-Medical Technology Co.,Ltd
    China
    		 BrightGene Pharmaceutical Co. , Ltd. 304MF10030 Eribulin mesylate 2022-02-10 2022-02-10 Building C25-C28, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, China 215123
    26/09/2024 Eisai
    Japan
    		 Eisai Co., Ltd. 301MF10104 Eribulin mesylate 2019-12-10 2019-12-10 4-6-10 Koishikawa, Bunkyo-ku, Tokyo